glp-1 weight loss no insurance Why payers are hesitant to cover drugs for Medically Supervised GLP-1 Weight Loss

Notably, J-1370 requires concurrent moderate- or high-intensity statin therapy, or documented statin intolerance, as a condition for coverage an unusual, Highmark-specific requirement beyond the standard established-CVD PA criteria

To that end, internists and other (largely OB/GYN and cardiology) specialists are adding GLP-1s to their prescribing and growing quickly within the prescribing pool

Reach more states and build enterprise readiness Multi-state expansion means multi-state licensing, state-specific telehealth and prescribing rules, and tax compliance everywhere you operate

Injection site (abdomen, thigh, or upper arm) may cause minor variations in absorption rate, but these differences are not clinically significant

doi: 10.1097/MD.0000000000000647

These risks primarily involved the digestive system and included nausea and vomiting, stomach pain, heartburn and gastroparesis, or stomach paralysis